(UPI) – A panel of U.S. Food and Drug Administration advisers on Thursday recommended approval for a new blood test to detect colon and rectal cancer despite concerns over the test’s accuracy. California-based biotechnology company Guardant Health applied for FDA approval of its blood test called Shield, which is used to screen for early signs of colorectal cancer. (Read More)